# Hematologic Malignancies

This section provides detailed underwriting guidelines for hematologic malignancies beyond leukemia and lymphoma, integrating modern classification, advanced treatments, and risk stratification approaches.

## Myelodysplastic Syndromes (MDS)

**Definition**: A group of diverse bone marrow disorders characterized by ineffective hematopoiesis, blood cell dysplasia, and variable risk of progression to acute myeloid leukemia (AML).

### Classification Systems

#### WHO Classification (2016)
- MDS with single lineage dysplasia (MDS-SLD)
- MDS with multilineage dysplasia (MDS-MLD)
- MDS with ring sideroblasts (MDS-RS)
- MDS with excess blasts (MDS-EB-1, MDS-EB-2)
- MDS with isolated del(5q)
- MDS, unclassifiable (MDS-U)

#### Risk Stratification
**International Prognostic Scoring System-Revised (IPSS-R)**:
- Very Low Risk (≤1.5 points)
- Low Risk (>1.5-3 points)
- Intermediate Risk (>3-4.5 points)
- High Risk (>4.5-6 points)
- Very High Risk (>6 points)

### Required Evidence

1. **Minimum Documentation**:
   - Bone marrow aspiration and biopsy reports
   - Complete blood count with differential
   - Cytogenetic analysis results
   - IPSS-R score calculation
   - Treatment history and response
   - Transfusion history and frequency
   - Blast percentage documentation
   - Progression history (if any)
   - Follow-up schedule

2. **Additional Evidence**:
   - Molecular testing results (if performed)
   - Documentation of iron overload assessment
   - Hypomethylating agent response
   - Bone marrow transplantation details (if performed)

### Underwriting Guidelines

| Risk Category | Treatment Status | Duration | Rating |
|--------------|-----------------|----------|--------|
| **Very Low IPSS-R** | Observation | <12 months | Table 4-5 |
| **Very Low IPSS-R** | Observation | 12-36 months | Table 3-4 |
| **Very Low IPSS-R** | Observation | >36 months | Table 2-3 |
| **Low IPSS-R** | Any | <12 months | Table 5-6 |
| **Low IPSS-R** | Any | 12-36 months | Table 4-5 |
| **Low IPSS-R** | Any | >36 months | Table 3-4 |
| **Intermediate IPSS-R** | Any | <24 months | Table 6-8 |
| **Intermediate IPSS-R** | Any | 24-48 months | Table 5-7 |
| **Intermediate IPSS-R** | Any | >48 months | Table 4-6 |
| **High IPSS-R** | Any | <36 months | Table 8-10 or Postpone |
| **High IPSS-R** | Any | >36 months | Table 6-8 |
| **Very High IPSS-R** | Any | Any | Table 9+ or Decline |
| **Any Risk** | Allogeneic SCT | <24 months | Table 8+ or Postpone |
| **Any Risk** | Allogeneic SCT | 24-60 months | Table 6-8 |
| **Any Risk** | Allogeneic SCT | >60 months | Table 4-6 |

**Modifying Factors**:
- MDS with isolated del(5q) and lenalidomide response: -1 table
- Red blood cell transfusion dependence: +1 table
- Platelet transfusion dependence: +2 tables
- Excess blasts (>5%): +1 table
- Stable blood counts for >24 months: -1 table
- MDS secondary to chemotherapy/radiation: +1 table
- MDS with fibrosis: +1 table
- Complex karyotype (≥3 abnormalities): +1 table
- Chronic infections due to neutropenia: +1 table
- Progression in blast percentage: +2 tables or postpone

### Progression to AML
- If progression to AML has occurred, rate according to AML guidelines with additional +1 table for MDS history

## Multiple Myeloma and Plasma Cell Disorders

### Multiple Myeloma

**Definition**: A malignancy of plasma cells characterized by monoclonal immunoglobulin production, bone lesions, and end-organ damage.

#### Staging Systems
**Revised International Staging System (R-ISS)**:
- Stage I: ISS stage I, standard-risk chromosomes, normal LDH
- Stage II: Not Stage I or III
- Stage III: ISS stage III and either high-risk chromosomes or high LDH

#### Risk Stratification
**High-risk cytogenetics**:
- t(4;14)
- t(14;16)
- t(14;20)
- del(17p)
- Gain(1q)

### Required Evidence

1. **Minimum Documentation**:
   - Bone marrow biopsy with plasma cell percentage
   - Serum and urine protein electrophoresis
   - Serum free light chain assay
   - Cytogenetic/FISH analysis
   - Imaging studies (skeletal survey, CT, MRI, PET)
   - Complete treatment history and response
   - Most recent oncology notes
   - Blood counts, calcium, creatinine, albumin, LDH
   - Minimal residual disease (MRD) testing (if performed)
   - ECOG performance status

2. **Additional Evidence**:
   - Autologous stem cell transplantation details
   - Maintenance therapy information
   - Disease progression history
   - Treatment complications

### Underwriting Guidelines

| Stage | Treatment Response | Time Since Diagnosis | Rating |
|-------|-------------------|---------------------|--------|
| **Smoldering MM** | Observation | <12 months | Table 5-6 |
| **Smoldering MM** | Observation | 12-36 months | Table 4-5 |
| **Smoldering MM** | Observation | >36 months | Table 3-4 |
| **Stage I-II** | Complete Response (CR) | <24 months | Table 6-8 |
| **Stage I-II** | Complete Response (CR) | 24-60 months | Table 5-7 |
| **Stage I-II** | Complete Response (CR) | >60 months | Table 4-6 |
| **Stage I-II** | Very Good Partial Response (VGPR) | <24 months | Table 7-9 |
| **Stage I-II** | Very Good Partial Response (VGPR) | 24-60 months | Table 6-8 |
| **Stage I-II** | Very Good Partial Response (VGPR) | >60 months | Table 5-7 |
| **Stage III** | Complete Response (CR) | <24 months | Table 7-9 |
| **Stage III** | Complete Response (CR) | 24-60 months | Table 6-8 |
| **Stage III** | Complete Response (CR) | >60 months | Table 5-7 |
| **Stage III** | Very Good Partial Response (VGPR) | <60 months | Table 8-10 |
| **Stage III** | Very Good Partial Response (VGPR) | >60 months | Table 6-8 |
| **Any Stage** | Partial Response (PR) | <60 months | Table 8+ or Postpone |
| **Any Stage** | Partial Response (PR) | >60 months | Table 7-9 |
| **Any Stage** | Post-ASCT with CR | <24 months | Table 6-8 |
| **Any Stage** | Post-ASCT with CR | 24-60 months | Table 5-7 |
| **Any Stage** | Post-ASCT with CR | >60 months | Table 4-6 |
| **Any Stage** | Relapsed/Refractory | Any | Postpone or Decline |
| **Any Stage** | Progressive Disease | Any | Decline |

**Modifying Factors**:
- High-risk cytogenetics: +1 table
- MRD negative status >12 months: -1 table
- Renal insufficiency: +1 table
- Extensive bone disease at diagnosis: +1 table
- Early relapse (<2 years): +2 tables
- Multiple relapses: +2 tables or decline
- Secondary plasma cell leukemia: Decline
- Sustained CR >5 years: -1 table
- Ongoing maintenance therapy with stable disease: No additional rating

### Monoclonal Gammopathy of Undetermined Significance (MGUS)

**Definition**: Presence of a monoclonal protein without evidence of multiple myeloma, Waldenström macroglobulinemia, amyloidosis, or other related disorders.

#### Risk Stratification
- **Low risk**: M-protein <1.5 g/dL, IgG type, normal free light chain ratio
- **Intermediate risk**: Any one factor abnormal
- **High risk**: Two or more factors abnormal

### Underwriting Guidelines for MGUS

| Risk Level | Duration | Rating |
|------------|----------|--------|
| **Low risk** | <12 months | Table 2-3 |
| **Low risk** | 12-60 months | Table 1-2 |
| **Low risk** | >60 months | Standard to Table 1 |
| **Intermediate risk** | <12 months | Table 3-4 |
| **Intermediate risk** | 12-60 months | Table 2-3 |
| **Intermediate risk** | >60 months | Table 1-2 |
| **High risk** | <12 months | Table 4-5 |
| **High risk** | 12-60 months | Table 3-4 |
| **High risk** | >60 months | Table 2-3 |

**Modifying Factors**:
- Annual M-protein increase >0.5 g/dL: +1 table
- Stable M-protein for >5 years: -1 table
- Abnormal bone marrow plasma cell percentage (>10%): +1 table
- Associated polyneuropathy: +1 table
- Evidence of end-organ damage: Rate as multiple myeloma
- Progression to myeloma: Rate as multiple myeloma

### Waldenström Macroglobulinemia (WM)

**Definition**: A type of non-Hodgkin lymphoma characterized by bone marrow infiltration with lymphoplasmacytic cells and an IgM monoclonal gammopathy.

#### Risk Stratification (International Prognostic Scoring System for WM)
- **Low risk**: Age ≤65 years, Hb ≥11.5 g/dL, platelets ≥100 × 10⁹/L, β2-microglobulin <3 mg/L, and serum monoclonal protein <70 g/L
- **Intermediate risk**: One or two adverse characteristics
- **High risk**: More than two adverse characteristics

### Underwriting Guidelines for WM

| Risk Level | Treatment Status | Duration | Rating |
|------------|-----------------|----------|--------|
| **Low risk** | Watch and wait | <24 months | Table 3-4 |
| **Low risk** | Watch and wait | 24-60 months | Table 2-3 |
| **Low risk** | Watch and wait | >60 months | Table 1-2 |
| **Low risk** | Treatment with response | <24 months | Table 4-5 |
| **Low risk** | Treatment with response | 24-60 months | Table 3-4 |
| **Low risk** | Treatment with response | >60 months | Table 2-3 |
| **Intermediate risk** | Any | <24 months | Table 5-6 |
| **Intermediate risk** | Any | 24-60 months | Table 4-5 |
| **Intermediate risk** | Any | >60 months | Table 3-4 |
| **High risk** | Any | <36 months | Table 6-8 |
| **High risk** | Any | 36-60 months | Table 5-7 |
| **High risk** | Any | >60 months | Table 4-6 |
| **Any risk** | Multiple treatments | <36 months | Table 6-8 |
| **Any risk** | Multiple treatments | >36 months | Table 5-7 |
| **Any risk** | Progressive disease | Any | Table 8+ or Decline |

**Modifying Factors**:
- Hyperviscosity syndrome: +1 table
- MYD88 L265P mutation: -1 table
- CXCR4 mutation: +1 table
- IgM level >5000 mg/dL: +1 table
- Cryoglobulinemia: +1 table
- Amyloidosis: +2 tables or decline
- Response to BTK inhibitors: -1 table
- Transformed to aggressive lymphoma: Rate per lymphoma guidelines + 2 tables

## Myeloproliferative Neoplasms (MPNs)

**Definition**: A group of clonal hematopoietic stem cell disorders characterized by overproduction of one or more myeloid cell lines.

### Major Types
- Polycythemia Vera (PV)
- Essential Thrombocythemia (ET)
- Primary Myelofibrosis (PMF)
- Chronic Neutrophilic Leukemia (CNL)
- Chronic Eosinophilic Leukemia, NOS (CEL)
- MPN, unclassifiable

### Required Evidence

1. **Minimum Documentation**:
   - Complete blood count with differential
   - Bone marrow biopsy reports
   - Molecular testing (JAK2, CALR, MPL, others as appropriate)
   - Treatment history and response
   - Thrombotic/hemorrhagic event history
   - Spleen size documentation
   - Constitutional symptoms assessment
   - Fibrosis grade (for myelofibrosis)
   - Progression history (if any)

2. **Additional Evidence**:
   - NGS panel results (if performed)
   - Documentation of disease complications
   - Risk stratification scores
   - Cytogenetic analysis

### Polycythemia Vera (PV)

#### Risk Stratification
- **Low risk**: Age <60 years and no history of thrombosis
- **High risk**: Age ≥60 years or history of thrombosis

#### Underwriting Guidelines for PV

| Risk Level | Disease Control | Duration | Rating |
|------------|----------------|----------|--------|
| **Low risk** | Well-controlled | <24 months | Table 3-4 |
| **Low risk** | Well-controlled | 24-60 months | Table 2-3 |
| **Low risk** | Well-controlled | >60 months | Table 1-2 |
| **High risk** | Well-controlled | <24 months | Table 4-6 |
| **High risk** | Well-controlled | 24-60 months | Table 3-5 |
| **High risk** | Well-controlled | >60 months | Table 2-4 |
| **Any risk** | Suboptimal control | <24 months | Table 5-7 |
| **Any risk** | Suboptimal control | 24-60 months | Table 4-6 |
| **Any risk** | Suboptimal control | >60 months | Table 3-5 |
| **Any risk** | Post-thrombotic event | <24 months | Table 6-8 |
| **Any risk** | Post-thrombotic event | >24 months | Table 4-6 |
| **Any risk** | Transformation to MF | <36 months | Table 6-8 |
| **Any risk** | Transformation to MF | >36 months | See PMF |
| **Any risk** | Transformation to AML | Any | Decline |

**Modifying Factors**:
- Target hematocrit <45%: -1 table
- Persistent leukocytosis >15 x 10⁹/L: +1 table
- Requirement for cytoreductive therapy: +1 table
- Splenomegaly >5cm below costal margin: +1 table
- Multiple phlebotomies per year: +1 table
- JAK2 allele burden >50%: +1 table
- Stable disease >10 years: -1 table
- Multiple thrombotic events: +2 tables

### Essential Thrombocythemia (ET)

#### Risk Stratification
- **Very low risk**: Age ≤60 years, no thrombosis history, no JAK2/MPL mutation
- **Low risk**: Age ≤60 years, no thrombosis history, JAK2/MPL mutation present
- **Intermediate risk**: Age >60 years, no thrombosis history, no JAK2/MPL mutation
- **High risk**: Age >60 years with JAK2/MPL mutation or thrombosis history

#### Underwriting Guidelines for ET

| Risk Level | Disease Control | Duration | Rating |
|------------|----------------|----------|--------|
| **Very low risk** | Well-controlled | <24 months | Table 2-3 |
| **Very low risk** | Well-controlled | 24-60 months | Table 1-2 |
| **Very low risk** | Well-controlled | >60 months | Standard to Table 1 |
| **Low risk** | Well-controlled | <24 months | Table 3-4 |
| **Low risk** | Well-controlled | 24-60 months | Table 2-3 |
| **Low risk** | Well-controlled | >60 months | Table 1-2 |
| **Intermediate risk** | Well-controlled | <24 months | Table 4-5 |
| **Intermediate risk** | Well-controlled | 24-60 months | Table 3-4 |
| **Intermediate risk** | Well-controlled | >60 months | Table 2-3 |
| **High risk** | Well-controlled | <24 months | Table 5-6 |
| **High risk** | Well-controlled | 24-60 months | Table 4-5 |
| **High risk** | Well-controlled | >60 months | Table 3-4 |
| **Any risk** | Post-thrombotic event | <24 months | Table 6-8 |
| **Any risk** | Post-thrombotic event | >24 months | Table 4-6 |
| **Any risk** | Transformation to MF | <36 months | Table 6-8 |
| **Any risk** | Transformation to MF | >36 months | See PMF |
| **Any risk** | Transformation to AML | Any | Decline |

**Modifying Factors**:
- CALR mutation (vs JAK2): -1 table
- Persistent extreme thrombocytosis (>1000 x 10⁹/L): +1 table
- Bleeding history: +1 table
- Stable disease >10 years: -1 table
- Acquired von Willebrand syndrome: +1 table
- Multiple thrombotic events: +2 tables

### Primary Myelofibrosis (PMF)

#### Risk Stratification (DIPSS-Plus)
- **Low risk**: 0 points
- **Intermediate-1 risk**: 1 point
- **Intermediate-2 risk**: 2-3 points
- **High risk**: ≥4 points

#### Underwriting Guidelines for PMF

| Risk Level | Treatment | Duration | Rating |
|------------|----------|----------|--------|
| **Low risk** | Any | <24 months | Table 5-7 |
| **Low risk** | Any | 24-60 months | Table 4-6 |
| **Low risk** | Any | >60 months | Table 3-5 |
| **Intermediate-1** | Any | <24 months | Table 6-8 |
| **Intermediate-1** | Any | 24-60 months | Table 5-7 |
| **Intermediate-1** | Any | >60 months | Table 4-6 |
| **Intermediate-2** | Any | <36 months | Table 7-9 |
| **Intermediate-2** | Any | 36-60 months | Table 6-8 |
| **Intermediate-2** | Any | >60 months | Table 5-7 |
| **High risk** | Any | <36 months | Postpone or Decline |
| **High risk** | Any | >36 months | Table 7-9 |
| **Any risk** | Allogeneic SCT | <24 months | Table 8+ or Postpone |
| **Any risk** | Allogeneic SCT | 24-60 months | Table 6-8 |
| **Any risk** | Allogeneic SCT | >60 months | Table 5-7 |
| **Any risk** | Blast phase | Any | Decline |

**Modifying Factors**:
- CALR type 1 mutation: -1 table
- Triple negative (JAK2, CALR, MPL negative): +1 table
- Transfusion dependence: +1 table
- Significant constitutional symptoms: +1 table
- Massive splenomegaly (>10cm below costal margin): +1 table
- Grade 3 fibrosis: +1 table
- Response to ruxolitinib with symptom improvement: -1 table
- High molecular risk mutations: +1 table

## Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangements

**Definition**: A group of rare disorders characterized by eosinophilia and specific genetic abnormalities, primarily tyrosine kinase gene fusions.

### Major Subtypes
- PDGFRA-rearranged myeloid/lymphoid neoplasms
- PDGFRB-rearranged myeloid neoplasms
- FGFR1-rearranged myeloid/lymphoid neoplasms
- PCM1-JAK2 rearrangement
- ETV6-ABL1 fusion and other rare translocations

### Underwriting Guidelines

| Subtype | Treatment Response | Duration | Rating |
|---------|-------------------|----------|--------|
| **PDGFRA-rearranged** | Complete response to TKI | <24 months | Table 4-6 |
| **PDGFRA-rearranged** | Complete response to TKI | 24-60 months | Table 3-5 |
| **PDGFRA-rearranged** | Complete response to TKI | >60 months | Table 2-4 |
| **PDGFRB-rearranged** | Complete response to TKI | <24 months | Table 5-7 |
| **PDGFRB-rearranged** | Complete response to TKI | 24-60 months | Table 4-6 |
| **PDGFRB-rearranged** | Complete response to TKI | >60 months | Table 3-5 |
| **FGFR1-rearranged** | Any | <60 months | Table 7-9 |
| **FGFR1-rearranged** | Any | >60 months | Table 6-8 |
| **Any subtype** | Blast transformation | Any | Decline |

**Modifying Factors**:
- Organ damage due to eosinophilia: +1 table
- Stable molecular remission >3 years: -1 table
- TKI resistance: +2 tables
- Lymphoid presentation: +1 table

## Histiocytic Disorders

### Langerhans Cell Histiocytosis (LCH)

**Definition**: A rare disorder characterized by abnormal proliferation of Langerhans cells, which may affect single or multiple organ systems.

#### Risk Stratification
- **Low-risk**: Single-system disease or multisystem disease without risk organ involvement
- **High-risk**: Multisystem disease with risk organ involvement (liver, spleen, hematopoietic system)

#### Underwriting Guidelines for LCH

| Risk Level | Disease Status | Duration | Rating |
|------------|---------------|----------|--------|
| **Single-system, bone only** | Resolution | <24 months | Table 3-4 |
| **Single-system, bone only** | Resolution | 24-60 months | Table 2-3 |
| **Single-system, bone only** | Resolution | >60 months | Table 1-2 |
| **Single-system, other** | Resolution | <24 months | Table 4-5 |
| **Single-system, other** | Resolution | 24-60 months | Table 3-4 |
| **Single-system, other** | Resolution | >60 months | Table 2-3 |
| **Multisystem, low-risk** | Resolution | <24 months | Table 5-6 |
| **Multisystem, low-risk** | Resolution | 24-60 months | Table 4-5 |
| **Multisystem, low-risk** | Resolution | >60 months | Table 3-4 |
| **Multisystem, high-risk** | Resolution | <36 months | Table 6-8 |
| **Multisystem, high-risk** | Resolution | 36-60 months | Table 5-7 |
| **Multisystem, high-risk** | Resolution | >60 months | Table 4-6 |
| **Any type** | Active disease | Any | Postpone |
| **Any type** | Neurodegenerative LCH | Any | Table 7+ or Decline |

**Modifying Factors**:
- BRAF V600E mutation: +1 table
- Permanent organ dysfunction: +1 to 3 tables based on severity
- Multiple reactivations: +1 table
- Childhood disease with long-term remission into adulthood: -1 table
- Diabetes insipidus: +1 table
- Pulmonary involvement: +1 table

### Erdheim-Chester Disease (ECD) and Other Histiocytoses

**Definition**: Rare non-Langerhans cell histiocytosis characterized by tissue infiltration with histiocytes, primarily affecting adults.

#### Underwriting Guidelines for ECD and Other Histiocytoses

| Disease | Treatment Response | Duration | Rating |
|---------|-------------------|----------|--------|
| **ECD** | Stable disease on BRAF inhibitor | <36 months | Table 6-8 |
| **ECD** | Stable disease on BRAF inhibitor | >36 months | Table 5-7 |
| **ECD** | Otherwise controlled | <36 months | Table 7-9 |
| **ECD** | Otherwise controlled | >36 months | Table 6-8 |
| **Rosai-Dorfman Disease** | Resolution | <24 months | Table 4-6 |
| **Rosai-Dorfman Disease** | Resolution | >24 months | Table 3-5 |
| **Hemophagocytic Lymphohistiocytosis** | Resolution | <36 months | Table 6-8 |
| **Hemophagocytic Lymphohistiocytosis** | Resolution | >36 months | Table 5-7 |
| **Any histiocytosis** | Progressive disease | Any | Postpone or Decline |

**Modifying Factors**:
- Cardiac involvement in ECD: +2 tables or decline
- CNS involvement: +2 tables
- Familial HLH: Individual consideration
- Recent immunosuppressive therapy: +1 table
- Secondary HLH: Rate for underlying condition +1 table

## Special Considerations

### Aplastic Anemia

**Definition**: Bone marrow failure characterized by pancytopenia and hypocellular bone marrow without abnormal cells.

#### Underwriting Guidelines for Aplastic Anemia

| Severity | Treatment Response | Duration | Rating |
|----------|-------------------|----------|--------|
| **Mild** | Partial/Complete recovery | <12 months | Table 4-6 |
| **Mild** | Partial/Complete recovery | 12-36 months | Table 3-5 |
| **Mild** | Partial/Complete recovery | >36 months | Table 2-4 |
| **Moderate** | Partial/Complete recovery | <24 months | Table 5-7 |
| **Moderate** | Partial/Complete recovery | 24-60 months | Table 4-6 |
| **Moderate** | Partial/Complete recovery | >60 months | Table 3-5 |
| **Severe** | Post-immunosuppressive therapy with response | <36 months | Table 6-8 |
| **Severe** | Post-immunosuppressive therapy with response | 36-60 months | Table 5-7 |
| **Severe** | Post-immunosuppressive therapy with response | >60 months | Table 4-6 |
| **Severe** | Post-allogenic SCT | <36 months | Table 7-9 |
| **Severe** | Post-allogenic SCT | 36-60 months | Table 6-8 |
| **Severe** | Post-allogenic SCT | >60 months | Table 5-7 |
| **Any** | Transfusion dependent | Any | Postpone or Decline |
| **Any** | Clonal evolution to MDS/AML | Any | Rate as MDS/AML |

**Modifying Factors**:
- Paroxysmal nocturnal hemoglobinuria (PNH) clone: +1 table
- Telomere abnormalities: +1 table
- Normal blood counts >3 years: -1 table
- Recurrent infections: +1 table
- Ongoing low-dose immunosuppression: +1 table
- Prior androgen therapy with liver dysfunction: +1 table

### Paroxysmal Nocturnal Hemoglobinuria (PNH)

**Definition**: An acquired clonal disorder resulting from a somatic mutation in the PIGA gene in hematopoietic stem cells, causing complement-mediated hemolysis.

#### Risk Stratification
- **Subclinical PNH**: Small PNH clone (<10%) without hemolysis or thrombosis
- **Classic PNH**: Hemolysis with or without thrombosis
- **PNH with bone marrow failure**: Concurrent aplastic anemia or MDS

#### Underwriting Guidelines for PNH

| Type | Treatment Status | Duration | Rating |
|------|----------------|----------|--------|
| **Subclinical PNH** | Observation only | <24 months | Table 3-5 |
| **Subclinical PNH** | Observation only | 24-60 months | Table 2-4 |
| **Subclinical PNH** | Observation only | >60 months | Table 1-3 |
| **Classic PNH** | On complement inhibitor | <24 months | Table 5-7 |
| **Classic PNH** | On complement inhibitor | 24-60 months | Table 4-6 |
| **Classic PNH** | On complement inhibitor | >60 months | Table 3-5 |
| **PNH with AA/MDS** | Controlled | <36 months | Table 6-8 |
| **PNH with AA/MDS** | Controlled | >36 months | Table 5-7 |
| **Any PNH** | Post-thrombotic event | <36 months | Table 7-9 or Postpone |
| **Any PNH** | Post-thrombotic event | >36 months | Table 6-8 |
| **Any PNH** | Post-allogenic SCT | <36 months | Table 7-9 |
| **Any PNH** | Post-allogenic SCT | 36-60 months | Table 6-8 |
| **Any PNH** | Post-allogenic SCT | >60 months | Table 5-7 |

**Modifying Factors**:
- Hemoglobin <10 g/dL despite treatment: +1 table
- LDH >1.5x upper limit of normal despite treatment: +1 table
- Multiple thrombotic events: +2 tables or decline
- Stable disease >5 years on complement inhibitor: -1 table
- Renal dysfunction: +1 table
- PNH clone size >50%: +1 table
- Recurrent breakthrough hemolysis: +1 table

## Novel Therapies and Special Treatment Considerations

### CAR T-Cell Therapy

| Indication | Response | Time Since Treatment | Rating |
|------------|----------|---------------------|--------|
| **B-ALL** | Complete response | <12 months | Table 6-8 |
| **B-ALL** | Complete response | 12-36 months | Table 5-7 |
| **B-ALL** | Complete response | >36 months | Table 4-6 |
| **DLBCL** | Complete response | <12 months | Table 6-8 |
| **DLBCL** | Complete response | 12-36 months | Table 5-7 |
| **DLBCL** | Complete response | >36 months | Table 4-6 |
| **Multiple myeloma** | Complete/VGPR | <12 months | Table 7-9 |
| **Multiple myeloma** | Complete/VGPR | 12-36 months | Table 6-8 |
| **Multiple myeloma** | Complete/VGPR | >36 months | Table 5-7 |
| **Any indication** | Partial response | <24 months | Postpone |
| **Any indication** | Partial response | >24 months | Individual consideration |

**Modifying Factors**:
- Grade 3-4 cytokine release syndrome: +1 table
- Neurotoxicity with residual effects: +1 to 2 tables
- Multiple CAR T infusions: +1 table
- Early relapse after CAR T (<6 months): +2 tables or decline

### Targeted Therapies

| Therapy Type | Disease | Response | Rating Consideration |
|--------------|---------|----------|---------------------|
| **BTK Inhibitors** | CLL/MCL/WM | Responsive | No additional rating beyond disease |
| **BCL-2 Inhibitors** | AML/CLL | Responsive | No additional rating beyond disease |
| **IDH1/2 Inhibitors** | AML/MDS | Responsive | No additional rating beyond disease |
| **FLT3 Inhibitors** | AML | Responsive | No additional rating beyond disease |
| **JAK Inhibitors** | MPN | Responsive | -1 table if symptoms controlled |
| **BRAF Inhibitors** | HCL/Histiocytosis | Responsive | -1 table if sustained response |
| **BiTE Antibodies** | ALL/Lymphomas | Responsive | No additional rating beyond disease |
| **ADCs** | Various | Responsive | No additional rating beyond disease |
| **Checkpoint Inhibitors** | Lymphomas | Responsive | +1 table (immune-related risks) |

## Risk Factors and Complications

### Secondary Malignancies

| Primary Hematologic Malignancy | Secondary Malignancy | Time Frame | Rating Adjustment |
|-------------------------------|---------------------|------------|-------------------|
| **Lymphoma with chemotherapy** | Secondary MDS/AML | <5 years | +2 tables to base rating or decline |
| **Multiple myeloma** | Secondary MDS/AML | <5 years | +2 tables to base rating or decline |
| **MPN** | AML transformation | <2 years | Decline |
| **Any with ASCT** | Secondary malignancy | <5 years | +2 tables to base rating |
| **Any with radiation** | Solid tumor in field | <5 years | +1 table to base rating |

### Treatment-Related Complications

| Complication | Severity | Rating Impact |
|--------------|----------|--------------|
| **Cardiomyopathy** | Mild (EF 45-55%) | +1 table |
| **Cardiomyopathy** | Moderate (EF 35-45%) | +2 tables |
| **Cardiomyopathy** | Severe (EF <35%) | +3 tables or decline |
| **Pulmonary fibrosis** | Mild | +1 table |
| **Pulmonary fibrosis** | Moderate to severe | +2 to 3 tables |
| **Chronic GVHD** | Mild, controlled | +1 table |
| **Chronic GVHD** | Moderate | +2 tables |
| **Chronic GVHD** | Severe | +3 tables or decline |
| **Secondary endocrine disorders** | Controlled | +1 table |
| **Iron overload** | Treated | +1 table |
| **Renal dysfunction** | Mild to moderate | +1 to 2 tables |
| **Renal dysfunction** | Severe | +3 tables or decline |
| **Chronic infections** | Recurrent | +1 to 2 tables |
| **Neurocognitive impairment** | Mild | +1 table |
| **Neurocognitive impairment** | Moderate to severe | +2 to 3 tables |

## Postpone/Decline Criteria

### Postpone

1. Recently diagnosed hematologic malignancy (<3-6 months)
2. Currently receiving active induction or high-intensity therapy
3. Undergoing evaluation for disease progression
4. Less than 6 months from stem cell transplantation
5. Less than 3 months from CAR T-cell therapy
6. Active severe GVHD
7. Recent thrombotic event (<6 months) in MPN
8. Pending genetic/molecular testing for prognosis
9. Recent blast phase in CML (<12 months) with return to chronic phase
10. Pending transplant evaluation
11. Recent grade 3-4 treatment toxicity (<3 months)

### Decline

1. Progressive or refractory acute leukemia
2. Blast transformation of MPN without return to chronic phase
3. High-risk MDS with progression or transfusion dependence
4. Multiple myeloma with aggressive disease features and inadequate response
5. Life-threatening or uncontrolled complications of therapy
6. Active secondary cancer with poor prognosis
7. Severe, refractory GVHD
8. End-stage organ damage from disease or treatment
9. Multiple thrombotic events in MPN despite treatment
10. Failed multiple lines of therapy with progressive disease
11. CNS involvement with active disease
12. ECOG performance status ≥3

## References

1. World Health Organization Classification of Haematopoietic and Lymphoid Tissues (2016, revised 2022)
2. National Comprehensive Cancer Network (NCCN) Guidelines
3. European LeukemiaNet (ELN) Recommendations
4. International Prognostic Scoring Systems (IPSS-R, DIPSS-Plus, ISS-R)
5. American Society of Hematology (ASH) Guidelines
6. European Society for Medical Oncology (ESMO) Clinical Practice Guidelines
7. International Working Group (IWG) Response Criteria for various hematologic malignancies
8. International Myeloma Working Group (IMWG) diagnostic and response criteria